Hepatocellular carcinoma in the noncirrhotic liver

American Journal of Roentgenology

Volumn 203, Issue 1, 2014, Pages

  Gaddikeri, Santhosh ^a   McNeeley, Michael F ^a   Wang, Carolyn L ^a   Bhargava, Puneet ^b   Dighe, Manjiri K ^a   Yeh, Matthew M C ^c   Dubinsky, Theodore Jay ^a   Kolokythas, Orpheus ^d   Lalwani, Neeraj ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Kantonsspital Winterthur   (Switzerland)

Author keywords

Cirrhosis; CT; Hepatocellular carcinoma; MRI; Noncirrhotic liver; Risk factors

Indexed keywords

CONTRAST MEDIUM; DIAGNOSTIC AGENT; TUMOR MARKER;

CT; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TUMOR; NONCIRRHOTIC LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROGNOSIS; REVIEW; RISK FACTOR; SURVIVAL;

CIRRHOSIS; CT; HEPATOCELLULAR CARCINOMA; MRI; NONCIRRHOTIC LIVER; RISK FACTORS;

CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84906089820     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.13.11511     Document Type: Review

References (62)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108 (Pubitemid 40372904)
2. Trevisani F, Frigerio M, Santi V, Grignaschi A, Bernardi M. Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. Dig Liver Dis 2010; 42:341-347
3. Smalley SR, Moertel CG, Hilton JF, et al. Hepatoma in the noncirrhotic liver. Cancer 1988; 62:1414-1424
4. Nzeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma and nodular regenerative hyperplasia: possible pathogenetic relationship. Am J Gastroenterol 1996; 91:879-884 (Pubitemid 26143523)
5. Trevisani F, D'Intino PE, Caraceni P, et al. Etiologic factors and clinical presentation of hepatocellular carcinoma: differences between cirrhotic and noncirrhotic Italian patients. Cancer 1995; 75:2220-2232
6. Calvet X, Bruix J, Bru C, et al. Natural history of hepatocellular carcinoma in Spain: five years' experience in 249 cases. J Hepatol 1990; 10:311-317 (Pubitemid 20162738)
7. El-Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology 2004; 39:798-803 (Pubitemid 38337660)
8. Houben KW, McCall JL. Liver transplantation for hepatocellular carcinoma in patients without underlying liver disease: a systematic review. Liver Transpl Surg 1999; 5:91-95 (Pubitemid 29118209)
9. Brancatelli G, Federle MP, Grazioli L, Carr BI. Hepatocellular carcinoma in noncirrhotic liver: CT, clinical, and pathologic findings in 39 U.S. residents. Radiology 2002; 222:89-94 (Pubitemid 34031471)
10. Shanbhogue AK, Prasad SR, Takahashi N, Vikram R, Sahani DV. Recent advances in cytogenetics and molecular biology of adult hepatocellular tumors: implications for imaging and management. Radiology 2011; 258:673-693
11. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006; 6:674-687 (Pubitemid 44286000)
12. Boyault S, Rickman DS, de Reynies A, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007; 45:42-52 (Pubitemid 46144363)
13. Ray RB, Meyer K, Ray R. Hepatitis C virus core protein promotes immortalization of primary human hepatocytes. Virology 2000; 271:197-204 (Pubitemid 30341528)
14. el-Refaie A, Savage K, Bhattacharya S, et al. HCV-associated hepatocellular carcinoma without cirrhosis. J Hepatol 1996; 24:277-285 (Pubitemid 26104883)
15. Cieply B, Zeng G, Proverbs-Singh T, Geller DA, Monga SP. Unique phenotype of hepatocellular cancers with exon-3 mutations in betacatenin gene. Hepatology 2009; 49:821-831
16. Nash KL, Woodall T, Brown AS, Davies SE, Alexander GJ. Hepatocellular carcinoma in patients with chronic hepatitis C virus infection without cirrhosis. World J Gastroenterol 2010; 16:4061-4065
17. Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology 2004; 127(suppl 1):S87-S96 (Pubitemid 39423374)
18. Donato F, Tagger A, Chiesa R, et al. Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case-control study in Italy - Brescia HCC Study. Hepatology 1997; 26:579-584 (Pubitemid 27392347)
19. Ozturk M. p53 Mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 1991; 338:1356-1359
20. Qian GS, Ross RK, Yu MC, et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev 1994; 3:3-10 (Pubitemid 24172514)
21. Lipshutz GS, Brennan TV, Warren RS. Thorotrast-induced liver neoplasia: a collective review. J Am Coll Surg 2002; 195:713-718 (Pubitemid 35285406)
22. Turlin B, Juguet F, Moirand R, et al. Increased liver iron stores in patients with hepatocellular carcinoma developed on a noncirrhotic liver. Hepatology 1995; 22:446-450
23. Rudnick DA, Perlmutter DH. Alpha-1-antitrypsin deficiency: a new paradigm for hepatocellular carcinoma in genetic liver disease. Hepatology 2005; 42:514-521 (Pubitemid 41233640)
24. Fujihara S, Mori H, Kobara H, et al. Metabolic syndrome, obesity, and gastrointestinal cancer. Gastroenterol Res Pract 2012; 2012:483623
25. Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 2009; 115:5651-5661
26. Roskams T, Yang SQ, Koteish A, et al. Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol 2003; 163:1301-1311 (Pubitemid 37175079)
27. Hu W, Feng Z, Eveleigh J, et al. The major lipid peroxidation product, trans-4-hydroxy-2-nonenal, preferentially forms DNA adducts at codon 249 of human p53 gene, a unique mutational hotspot in hepatocellular carcinoma. Carcinogenesis 2002; 23:1781-1789 (Pubitemid 35355927)
28. Zucman-Rossi J, Jeannot E, Nhieu JT, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 2006; 43:515-524
29. Farges O, Ferreira N, Dokmak S, Belghiti J, Bedossa P, Paradis V. Changing trends in malignant transformation of hepatocellular adenoma. Gut 2011; 60:85-89
30. Farges O, Dokmak S. Malignant transformation of liver adenoma: an analysis of the literature. Dig Surg 2010; 27:32-38
31. Herman P, Coelho FF, Perini MV, Lupinacci RM, D'Albuquerque LA, Cecconello I. Hepatocellular adenoma: an excellent indication for laparoscopic liver resection. HPB (Oxford) 2012; 14:390-395
32. Cassiman D, Libbrecht L, Verslype C, et al. An adult male patient with multiple adenomas and a hepatocellular carcinoma: mild glycogen storage disease type Ia. J Hepatol 2010; 53:213-217
33. Neuberger J, Forman D, Doll R, Williams R. Oral contraceptives and hepatocellular carcinoma. Br Med J (Clin Res Ed) 1986; 292:1355-1357 (Pubitemid 16081814)
34. Takayasu K, Muramatsu Y, Moriyama N, et al. Radiological study of idiopathic Budd-Chiari syndrome complicated by hepatocellular carcinoma: a report of four cases. Am J Gastroenterol 1994; 89:249-253 (Pubitemid 24054188)
35. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37:1202-1219 [Erratum in: Hepatology 2003; 38:536] (Pubitemid 36538699)
36. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43(suppl 1):S99-S112
37. Bosman FTCF, Hruban RH, Theise ND, eds. World Health Organization classification of tumours: pathology and genetics of tumours of the digestive system. Lyon, France: IARC Press, 2010
38. Chung YE, Park MS, Park YN, et al. Hepatocellular carcinoma variants: radiologic-pathologic correlation. AJR 2009; 193:[web]W7-W13
39. Lubrano J, Huet E, Tsilividis B, et al. Long-term outcome of liver resection for hepatocellular carcinoma in noncirrhotic nonfibrotic liver with no viral hepatitis or alcohol abuse. World J Surg 2008; 32:104-109 (Pubitemid 50003884)
40. Bhaijee F, Krige JE, Locketz ML, Kew MC. Liver resection for non-cirrhotic hepatocellular carcinoma in South African patients. S Afr J Surg 2011; 49:68-74
41. Winston CB, Schwartz LH, Fong Y, Blumgart LH, Panicek DM. Hepatocellular carcinoma: MR imaging findings in cirrhotic livers and noncirrhotic livers. Radiology 1999; 210:75-79 (Pubitemid 29004286)
42. McLarney JK, Rucker PT, Bender GN, Goodman ZD, Kashitani N, Ros PR. Fibrolamellar carcinoma of the liver: radiologic-pathologic correlation. RadioGraphics 1999; 19:453-471
43. Stevens WR, Johnson CD, Stephens DH, Nagorney DM. Fibrolamellar hepatocellular carcinoma: stage at presentation and results of aggressive surgical management. AJR 1995; 164:1153-1158
44. Ichikawa T, Federle MP, Grazioli L, Madariaga J, Nalesnik M, Marsh W. Fibrolamellar hepatocellular carcinoma: imaging and pathologic findings in 31 recent cases. Radiology 1999; 213:352-361 (Pubitemid 29510577)
45. Corrigan K, Semelka RC. Dynamic con-trast- enhanced MR imaging of fibrolamellar hepatocellular carcinoma. Abdom Imaging 1995; 20:122-125
46. Blachar A, Federle MP, Ferris JV, et al. Radiologists' performance in the diagnosis of liver tumors with central scars by using specific CT criteria. Radiology 2002; 223:532-539 (Pubitemid 34454339)
47. Kanematsu M, Kondo H, Goshima S, Tsuge Y, Watanabe H. Magnetic resonance imaging of hepatocellular carcinoma. Oncology 2008; 75(suppl 1):65-71
48. Kawada N, Imanaka K, Kawaguchi T, et al. Hepatocellular carcinoma arising from noncirrhotic nonalcoholic steatohepatitis. J Gastroenterol 2009; 44:1190-1194
49. Yoshikawa J, Matsui O, Takashima T, et al. Fatty metamorphosis in hepatocellular carcinoma: radiologic features in 10 cases. AJR 1988; 151:717-720
50. Siripongsakun S, Lee JK, Raman SS, Tong MJ, Sayre J,Lu DS. MRI detection of intratumoral fat in hepatocellular carcinoma: potential biomarker for a more favorable prognosis. AJR 2012; 199:1018-1025
51. Honda H, Kaneko K, Maeda T, et al. Small hepatocellular carcinoma on magnetic resonance imaging: relation of signal intensity to angiographic and clinicopathologic findings. Invest Radiol 1997; 32:161-168 (Pubitemid 27093514)
52. Vandecaveye V, De Keyzer F, Verslype C, et al. Diffusion-weighted MRI provides additional value to conventional dynamic contrast-enhanced MRI for detection of hepatocellular carcinoma. Eur Radiol 2009; 19:2456-2466
53. Sandrasegaran K, Tahir B, Patel A, et al. The usefulness of diffusion-weighted imaging in the characterization of liver lesions in patients with cirrhosis. Clin Radiol 2013; 68:708-715
54. Kanematsu M, Goshima S, Watanabe H, et al. Diffusion/perfusion MR imaging of the liver: practice, challenges, and future. Magn Reson Med Sci 2012; 11:151-161
55. Muhi A, Ichikawa T, Motosugi U, et al. High-b-value diffusion-weighted MR imaging of hepatocellular lesions: estimation of grade of malignancy of hepatocellular carcinoma. J Magn Reson Imaging 2009; 30:1005-1011
56. Enomoto S, Tamai H, Shingaki N, et al. Assessment of hepatocellular carcinomas using conventional magnetic resonance imaging correlated with histological differentiation and a serum marker of poor prognosis. Hepatol Int 2011; 5:730-737
57. Ishigami K, Yoshimitsu K, Nishihara Y, et al. Hepatocellular carcinoma with a pseudocapsule on gadolinium-enhanced MR images: correlation with histopathologic findings. Radiology 2009; 250:435-443
58. Rummeny E, Weissleder R, Sironi S, et al. Central scars in primary liver tumors: MR features, specificity, and pathologic correlation. Radiology 1989; 171:323-326 (Pubitemid 19108093)
59. Kohno H, Nagasue N, Hayashi T, et al. Postoperative adjuvant chemotherapy after radical hepatic resection for hepatocellular carcinoma (HCC). Hepatogastroenterology 1996; 43:1405-1409 (Pubitemid 27007323)
60. Ono T, Nagasue N, Kohno H, et al. Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: a prospective randomized study. Semin Oncol 1997; 24(2 suppl 6):S6-18-S6-25
61. Itamoto T, Nakahara H, Amano H, et al. Repeat hepatectomy for recurrent hepatocellular carcinoma. Surgery 2007; 141:589-597 (Pubitemid 46628978)
62. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008; 7:3129-3140